Aytu BioPharma (NASDAQ:AYTU) Releases Earnings Results, Misses Expectations By $0.02 EPS

Aytu BioPharma (NASDAQ:AYTU) released its quarterly earnings data on Thursday. The company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02), FiscalAI reports. Aytu BioPharma had a negative net margin of 20.52% and a positive return on equity of 17.06%. The business had revenue of $13.89 million during the quarter, compared to analyst estimates of $17.92 million.

Aytu BioPharma Price Performance

Shares of NASDAQ AYTU opened at $2.09 on Friday. Aytu BioPharma has a 52 week low of $0.95 and a 52 week high of $2.82. The company’s 50-day moving average price is $2.21 and its 200 day moving average price is $2.12. The company has a current ratio of 1.26, a quick ratio of 1.07 and a debt-to-equity ratio of 0.57. The stock has a market cap of $21.29 million, a price-to-earnings ratio of -0.69 and a beta of 0.25.

Analysts Set New Price Targets

AYTU has been the topic of a number of recent research reports. Maxim Group lowered their price objective on Aytu BioPharma from $9.00 to $7.00 and set a “buy” rating on the stock in a research note on Thursday, September 25th. Zacks Research cut Aytu BioPharma from a “hold” rating to a “strong sell” rating in a report on Friday, October 10th. Ascendiant Capital Markets raised their target price on shares of Aytu BioPharma from $12.00 to $12.50 and gave the company a “buy” rating in a report on Thursday, September 25th. Wall Street Zen downgraded Aytu BioPharma from a “buy” rating to a “hold” rating in a report on Friday, September 26th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Aytu BioPharma in a research note on Tuesday, October 14th. Three research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $9.17.

Hedge Funds Weigh In On Aytu BioPharma

An institutional investor recently bought a new position in Aytu BioPharma stock. Dimensional Fund Advisors LP purchased a new position in shares of Aytu BioPharma Inc. (NASDAQ:AYTU) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 30,964 shares of the company’s stock, valued at approximately $58,000. Dimensional Fund Advisors LP owned 0.30% of Aytu BioPharma at the end of the most recent quarter. Institutional investors and hedge funds own 33.49% of the company’s stock.

About Aytu BioPharma

Aytu Biopharma, Inc is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers.